Kellie Lynn Smith, CRNA | |
35 Medical Center Pkwy Ste 201, Augusta, ME 04330-8160 | |
(207) 622-1959 | |
(207) 430-4007 |
Full Name | Kellie Lynn Smith |
---|---|
Gender | Female |
Speciality | Certified Registered Nurse Anesthetist (crna) |
Experience | 11 Years |
Location | 35 Medical Center Pkwy Ste 201, Augusta, Maine |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1467874776 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367500000X | Nurse Anesthetist, Certified Registered | RNA133026 (Maine) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Maine General Medical Center | Augusta, ME | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Kennebec Anesthesia Associates Pa | 8325027428 | 35 |
News Archive
Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.
Researchers have linked a variant in the vitamin D receptor gene (VDR) with the onset of chronic obstructive pulmonary disease (COPD) in Caucasian men. The study population consisted of participants in the Veterans Administration Normative Aging Study, a multidisciplinary study of aging that began in 1963.
NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.
Of the nearly 4 million women in the United States who have had either breast cancer or ovarian cancer, at least 1.5 million have a high risk of carrying certain types of genetic mutations that could increase their risk for additional cancers in the future.
Morinaga Milk Industry Co., Ltd., the second largest dairy product company in Japan, today announced that the U.S. Food and Drug Administration has issued Generally Recognized as Safe Letters of No Objection for Morinaga's proprietary probiotic strain, Bifidobacterium breve M-16V for food applications and infant formulas.
› Verified 3 days ago
Entity Name | Kennebec Anesthesia Associates Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1992789184 PECOS PAC ID: 8325027428 Enrollment ID: O20040714000140 |
News Archive
Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.
Researchers have linked a variant in the vitamin D receptor gene (VDR) with the onset of chronic obstructive pulmonary disease (COPD) in Caucasian men. The study population consisted of participants in the Veterans Administration Normative Aging Study, a multidisciplinary study of aging that began in 1963.
NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.
Of the nearly 4 million women in the United States who have had either breast cancer or ovarian cancer, at least 1.5 million have a high risk of carrying certain types of genetic mutations that could increase their risk for additional cancers in the future.
Morinaga Milk Industry Co., Ltd., the second largest dairy product company in Japan, today announced that the U.S. Food and Drug Administration has issued Generally Recognized as Safe Letters of No Objection for Morinaga's proprietary probiotic strain, Bifidobacterium breve M-16V for food applications and infant formulas.
› Verified 3 days ago
Entity Name | Collaborative Anesthesia Partners |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023522455 PECOS PAC ID: 9133482532 Enrollment ID: O20180418000373 |
News Archive
Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.
Researchers have linked a variant in the vitamin D receptor gene (VDR) with the onset of chronic obstructive pulmonary disease (COPD) in Caucasian men. The study population consisted of participants in the Veterans Administration Normative Aging Study, a multidisciplinary study of aging that began in 1963.
NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.
Of the nearly 4 million women in the United States who have had either breast cancer or ovarian cancer, at least 1.5 million have a high risk of carrying certain types of genetic mutations that could increase their risk for additional cancers in the future.
Morinaga Milk Industry Co., Ltd., the second largest dairy product company in Japan, today announced that the U.S. Food and Drug Administration has issued Generally Recognized as Safe Letters of No Objection for Morinaga's proprietary probiotic strain, Bifidobacterium breve M-16V for food applications and infant formulas.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Kellie Lynn Smith, CRNA 35 Medical Center Pkwy Ste 201, Augusta, ME 04330-8160 Ph: (207) 622-1959 | Kellie Lynn Smith, CRNA 35 Medical Center Pkwy Ste 201, Augusta, ME 04330-8160 Ph: (207) 622-1959 |
News Archive
Array BioPharma Inc. today announced that five abstracts have been selected for presentation at the American Association for Cancer Research Annual Meeting, being held from April 2-6, 2010, at the Orange County Convention Center in Orlando, Fla.
Researchers have linked a variant in the vitamin D receptor gene (VDR) with the onset of chronic obstructive pulmonary disease (COPD) in Caucasian men. The study population consisted of participants in the Veterans Administration Normative Aging Study, a multidisciplinary study of aging that began in 1963.
NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.
Of the nearly 4 million women in the United States who have had either breast cancer or ovarian cancer, at least 1.5 million have a high risk of carrying certain types of genetic mutations that could increase their risk for additional cancers in the future.
Morinaga Milk Industry Co., Ltd., the second largest dairy product company in Japan, today announced that the U.S. Food and Drug Administration has issued Generally Recognized as Safe Letters of No Objection for Morinaga's proprietary probiotic strain, Bifidobacterium breve M-16V for food applications and infant formulas.
› Verified 3 days ago
Stacey C Dostie, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 35 Medical Center Pkwy, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-430-4007 | |
Vanessa Railton, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 35 Medical Center Pkwy, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-430-4007 | |
Elisha Rose Coppens, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 35 Medical Center Pkwy # Pa, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-430-4007 | |
Sharon A Paradis, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 6 E Chestnut St, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-622-1959 | |
Ms. Edith June St. Pierre, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1 Va Ctr, Augusta, ME 04330 Phone: 207-623-8411 Fax: 207-621-4890 | |
Dana Jo Marshall, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 35 Medical Center Pkwy, Ste 201, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-430-4007 | |
Michael J Jose, C.R.N.A. Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 35 Medical Center Pkwy Ste 201, Augusta, ME 04330 Phone: 207-622-1959 Fax: 207-430-4007 |